CTOs on the Move

Curemark

www.curemark.com

 
Curemark, LLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Curemark`s pipeline includes preclinical and clinical-stage programs for the treatment of Autism, ADHD, addiction, Schizophrenia and Parkinson`s disease.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.curemark.com
  • 800 Westchester Avenue
    Rye Brook, NY USA 10573
  • Phone: 914.824.9700

Executives

Name Title Contact Details

Similar Companies

Flame Biosciences

Flame Biosciences is a clinical stage company focused on the research, development and commercialization of transformative therapies for cancer and other inflammatory conditions.

Just-Evotec Biologics

Just Evotec Biologics is an integrated design company that delivers advanced biotherapeutics discovery, CDMO capabilities and FIH to commercial manufacturing. They focus on accelerating and expanding access to biotherapeutics through scientific and tec...

Enzymatics

Enzymatics is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Axol Bioscience

We specialize in human cell culture. Whether you need iPSC-derived cells, disease models, human primary cells or culture media, were here for you.

Turnstone Biologics

Turnstone Biologics, a privately held clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading and complementary platforms that drive innate and adaptive tumor immunity, to provide benefit to the millions of cancer patients underserved by current treatment options. Turnstone`s proprietary vaccinia virus platform is engineered to drive coordinated immune activation, potent viral activity, and local expression of encoded therapeutics. The innovative TIL cell therapy platform leverages clinically validated treatment protocols and has been specifically designed to extend beyond the use of bulk TILs to enrich for the most relevant T-cells for tumor eradication, preserving broad antigen diversity and minimizing treatment times to patients. The Company has an ongoing Phase 1/2a trial in solid tumors (RAPTOR) for its leading oncolytic virus candidate, RIVAL-01, and is expecting to file an IND for the lead TIL therapy candidate, TIDAL-01, in 2021.